Loading
companiesCompany
Inovio Pharmaceuticals
Inovio is a US company developing DNA medicines delivered by electroporation, whose lead cancer-related programme VGX-3100 treats the HPV-caused precancerous cervical lesions that lead to cervical cancer.
Also called: InovioINOVIO Pharmaceuticals, Inc.
Overview
Inovio Pharmaceuticals, listed on Nasdaq, develops DNA plasmid immunotherapies and vaccines delivered into muscle or skin with a hand-held electroporation device. Its most advanced programme, VGX-3100, targets HPV 16 and 18 to clear high-grade cervical dysplasia (CIN2/3), the precancerous lesion that precedes cervical cancer, and completed the phase 3 REVEAL trials; the company has also run trials of DNA vaccines in HPV-related head and neck and anal cancers and in glioblastoma. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.
Headquarters
Plymouth Meeting, PA, US
Scorecard
All companies#423of 1244 companies, score 8
- phase 1/2 +1
- targets +2
- modalities +2
- registry trials +3
0 approved, 0 in phase 3, 1 earlier, 1 targets, 2 registry studies. Formula on the scorecards page.
Type
Stage
Public
Website
Phase 2vaccine
INO-5401 is an experimental cancer vaccine from Inovio Pharmaceuticals in phase 2 trials for glioma & glioblastoma, aimed at PSMA.